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Summary. Dopamine receptor agonists can be useful in the
treatment of hypertension or heart failure. Consequently,
the present study investigated the hemodynamic profile of
the novel dopamine D1/D2 receptor agonist Z1046 in open-
chest, pentobarbital-anesthetized swine. Z1046 was admin-
istered in a dose of 10 lg/kg (n 5 9) or 100 lg/kg (n 5 8),
which was injected over 1 minute; hemodynamic responses
were studied for 90 minutes after administration. Both
doses of Z1046 produced sustained decreases in mean aor-
tic blood pressure (15–20%). The hypotension produced by
the lower dose was principally due to a decrease in cardiac
output, as the trend toward a lower systemic vascular resis-
tance failed to reach levels of statistical significance. Con-
versely, the decrease in mean arterial blood pressure pro-
duced by the higher dose of Z1046 was mainly due to a
decrease in systemic vascular resistance (up to 17%), as the
trend toward a decrease in cardiac output at 60 and 90
minutes after administration was not different from the
changes in the saline-treated group. Heart rate decreased
slightly with both doses of Z1046. Z1046 decreased left
ventricular myocardial blood flow (up to 28 6 9%, p , 0.05)
in parallel with the decrease in myocardial oxygen con-
sumption (up to 24 6 7%, p , 0.05), with no change in the
transmural distribution of myocardial blood. Z1046 in a
dose of 10 lg/kg did not produce significant vasodilation of
regional vascular beds, but in a dose of 100 lg/kg produced
vasodilator responses in the small intestine (34 6 2% de-
crease in vascular resistance), spleen (43 6 7%), and kid-
neys (22 6 3% all p , 0.05 vs. baseline). In conclusion,
Z1046 produced systemic hypotension with negligible reflex
activation of sympathetic tone.
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In the early 1970s it became clear that dopamine pro-
duced vasodilation by a mechanism different from
beta-adrenoceptor activation [1]. Since that time, two
functionally separate dopamine (D) receptor subtypes
have become recognized. D1-like receptors are located
on the smooth muscle of arterial blood vessels that
supply the kidney, intestine, coronary, and cerebral
vessels, although the presence of D1-like receptors on
the latter two vessel types may be species dependent
[2–5]. Stimulation of these D1-like receptors produces
vasodilation. D1-like receptors are also located on renal
tubular cells (producing inhibition of Na1 reabsorp-
tion) and juxtaglomerular cells (producing increased
renin release), where they promote natriuresis and di-
uresis. D2-like receptors are situated on sympathetic
nerve endings (producing inhibition of norepin-
inephrine release), in the zona glomerulosa cells of the
adrenal cortex (producing inhibition of aldosterone re-
lease), and in sympathetic ganglia (producing inhibi-
tion of ganglionic transmission). Thus, while D1-like
receptors produce direct vasodilation and diuresis, D2-
like receptors modulate sympathetic nerve activity.
Experimental and clinical evidence is accumulating
that dopamine receptor agonists are useful in the treat-
ment of hypertension or congestive heart failure [1,5–
9]. In the present study we investigated the cardiovas-
cular actions of the novel mixed D1-like/D2-like agonist
Z1046 (Figure 1) [10–12]. Experiments were per-
formed in the same open-chest, anesthetized swine
model in which we performed earlier studies on
dopamine and the selective D1-like receptor agonist,
fenoldopam [5].
Materials and Methods
Studies were performed in accordance with the Guiding
Principles in the Care and Use of Laboratory Animals,
as approved by the Council of the American Physiologi-
cal Society, and with prior approval of the Animal Care
Committee of Erasmus University, Rotterdam.
Surgical instrumentation
Cross-bred Landrace 3 Yorkshire swines (HVC,
Hedel, The Netherlands) of either sex (n 5 21, 27 6 2
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kg) were sedated with an intramuscular injection of
ketamine (20 mg/kg) and were anesthetized with so-
dium pentobarbitone (20 mg/kg; Apharma, Arnhem,
The Netherlands) administered via a dorsal ear vein.
Animals were intubated and connected to a ventilator
for intermittent positive-pressure ventilation with a
mixture of oxygen and nitrogen (1:2). Respiratory rate
and tidal volume were adjusted to keep arterial blood
gases (ABL505, Radiometer, Copenhagen, Denmark)
within the physiological range. In the superior caval
vein a 7 French (r) catheter was placed for infusion of
5–10 mg/kg/h sodium pentobarbitone to maintain a con-
stant depth of anaesthesia. Catherers were also placed
in the superior vena cava for administration of saline or
Z1046. A 7 r Sensodyn micromanometer-tipped cathe-
ter (B. Braun Medical B.V., Oss, The Netherlands),
inserted via the left carotid artery, was used to meas-
ure left ventricular pressure and its first derivative
(LVdP/dt). The femoral arteries were cannulated with
8 r catheters, which were advanced into the descending
thoracic aorta for measurement of central aortic blood
pressure, for withdrawal of blood samples for blood gas
analysis, and for withdrawal of reference samples to
calibrate regional blood flows measured with the radio-
active microsphere technique. Rectal temperature was
monitored throughout the experiment and was main-
tained between 378C and 388C with external heating
pads and coverage of the animal with blankets.
After intravenous administration of 4 mg pan-
curonium bromide (Organon Teknika, Boxtel, The
Netherlands), a midline thoracotomy was performed,
and the heart was suspended in a pericardial cradle.
The left mammary vessels were ligated and the second
left rib removed for ease of further instrumentation.
The adventitia surrounding the aorta was dissected
free, and an electromagnetic flow probe (Skalar, Delft,
The Netherlands) was positioned around the artery for
measurement of ascending aortic blood flow (AoF). In
17 animals, the cardiac vein accompanying the left an-
terior descending (LAD) coronary artery was cannu-
lated for withdrawal of blood samples for determina-
tion of oxygen content. Myocardial oxygen consump-
tion (MVO2) was calculated as the product of myo-
cardial blood flow measured with radioactive
microspheres (see later) and the difference in the oxy-
gen content of the arterial and coronary venous blood.
Regional myocardial contractile function
Regional myocardial segment shortening was meas-
ured by sonomicrometry (Triton Technology, San Di-
ego, CA, USA) in 15 animals using one pair of ultra-
sonic crystals implanted approximately 10 mm apart in
the midmyocardial layer of the left ventricle. From the
tracings, segment shortening (SS) was computed as
SS (%) = 100 3 (EDL - ESL)/EDL,
where EDL and ESL are the segment length at end
diastole (onset of positive dP/dt) and end systole (20 ms
before the peak negative dP/dt), respectively.
Regional blood flow
To determine regional blood flows, the left atrial ap-
pendage of 17 animals was cannulated for injection of a
batch of 1–2 3 106 carbonized plastic microspheres (15
6 1 Lm [SD] in diameter) labeled with either 95Nb,
103Ru, 113Sn, or 141Ce. Starting 15 s before the injection
of microspheres, blood was withdrawn from the ab-
dominal aorta at a rate of 10 ml/min until 60 s after
completion of the injection of microspheres. After the
animals were killed with an overdose of sodium pento-
barbitone, various organs (lungs, adrenals, liver,
spleen, small intestine, brain, and kidneys) and tissues
(abdominal skin, various skeletal muscle groups) were
excised, weighed, and put into vials. The heart was
divided into the atria and right and left ventricle, and
fixed with formaldehyde (3.7% v/v). Two days later,
approximately 10 g of myocardium of the left ventricu-
lar free wall was divided into three layers of equal
thickness: the subepicardium, mesocardium, and
subendocardium. The radioactivity of the tissues and
blood samples was counted for 5 minutes in a gamma-
scintillation counter (Packard, Minaxi gamma)
equipped with a multichannel pulse height analyzer
(Conrac) using suitable energy windows for discrimi-
nating the different isotopes. The amount of blood flow
to the various tissues (Qtis) was calculated as:
Qtis(ml/min) = (itis/Iart) 3 Qart,
where Itis and Iart are the radioactivity (cpm) for each
isotope in a particular tissue and in the arterial blood
sample, respectively, and Qart is the rate of withdrawal
of the blood sample. The resistance of a particular tis-
sue was calculated as the ratio between the mean aor-
tic blood pressure and Qtis. The full details of the proce-
dures and calculation of the flow data using this
technique were reported earlier [13,14].
Fig. 1. Chemical structure of dopamine and Z1046 ((S)-6-
[[6[(2-(2-methoxyphenoxy)ethyl)amino] hexyl]propylamino]-
5,6,7,8-tetrahydro-1,2-naphtalenediol dihydrochloride).
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Experimental protocols
Following a 30-minute stabilization period, measure-
ments of systemic and coronary hemodynamic vari-
ables and regional myocardial segment length were
made. Blood samples were withdrawn from the aorta
and coronary vein, and microspheres were injected for
determination of regional blood flows. Then, animals
received either 10 ml saline (n 5 4) or Z1046 at a dose
of 10 lg/kg (n 5 9), or 100 lg/kg (n 5 8), dissolved in 10
ml of saline and injected intravenously over 2 minutes.
All hemodynamic and contractile function measure-
ments were repeated 5, 15, 30, 60, and 90 minutes after
the injection of saline or Z1046. Microsphere injections
were repeated at 5, 30, and 90 minutes following saline
or drug administration.
Data analysis
Intragroup comparison was performed using one-way
analysis of variance for repeated measures. When a
significant effect was observed, posthoc testing was
done using the paired t-test. Changes from baseline
produced by Z1046 were compared with the changes
from baseline in the saline-treated control group using
two-way analysis of variance for repeated measures. A
p value of a # 0.05 was considered statistically signifi-
cant (two tailed). All data are presented as the mean 6
SEM.
Drugs
Z1046 ((S)-6-[[6[[2-(2-methoxyphenoxy)ethyl]amino]
hexyl]propylamino]-5,6,7,8-tetrahydro-1,2-naphtalenedi
ol dihydrochloride; courtesy of Dr. F. Marchini, Zambon
Group, Italy) was dissolved in warm saline. Fresh drug
solutions were prepared on the day of each experiment.
Results
Systemic hemodynamics
Table 1 shows that there were no changes in any of the
systemic hemodynamics variables of the saline-treated
control animals during the 90-minute post–saline injec-
tion observation period, confirming earlier studies in
which we have also shown good stability of the open-
chest swine preparation over comparable time periods
[5,16]. Intravenous administration of Z1046 in a dose of
either 10 or 100 lg/kg produced significant decreases
(15–20%) in the mean arterial blood pressure within 15
minutes following injection that were sustained during
the remainder of the 90-minute observation period.
The hypotension produced by the lower dose was simi-
lar to the decrease in cardiac output, implying that
systemic vascular resistance (mean aortic pres-
sure/cardiac output) was not altered (p 5 NS vs. base-
line; p 5 NS vs. change in saline group). With the
higher dose, cardiac output remained essentially un-
changed, although there was a trend toward a decrease
at 60 and 90 minutes after administration (up to 10%;
p , 0.05 vs. baseline; p 5 NS vs. changes in saline
group). Consequently, the decrease in mean arterial
blood pressure produced by the higher dose of Z1046
was principally due to a decrease in systemic vascular
resistance (up to 17%). Heart rate decreased with both
doses of Z1046, although only with the lower dose was
significance reached. Stroke volume was not affected
by the low dose, but increased slightly and transiently
after administration of the high dose. LVdP/dtmax de-
creased with both doses, but this was likely due to the
decrease in diastolic arterial blood pressure (DAP) be-
cause LVdP/dtmax/DAP was not altered by either dose
of Z1046.
There were no changes in regional myocardial seg-
ment length at end-diastole or end-systole, nor in frac-
tional segment shortening in the saline-treated control
group during the 90-minute observation period. End-
diastolic and end-systolic segment lengths and, conse-
quently, systolic segment shortening, were not affected
by Z1046 in either dose.
Myocardial blood flow and oxygen
consumption
Table 2 shows that in the saline-treated control group
there were no changes in myocardial blood flow and
myocardial oxygen consumption during the 90-minute
observation period. Both doses of Z1046 produced a
small decrease in myocardial blood flow, parallel to the
decrease in the rate-pressure product (heart rate times
left ventricular systolic pressure). Myocardial oxygen
extraction (i.e., the difference between the arterial and
coronary venous oxygen contents expressed as a per-
cent of the arterial oxygen content) increased only
slightly following administration of Z1046, so that myo-
cardial oxygen consumption decreased with both doses
of Z1046.
Table 2 also shows that there were no changes in the
transmural distribution of myocardial blood in the sa-
line-treated control group. The Z1046-induced de-
crease in myocardial perfusion was similar in the inner
and outer layer of the left ventricular free wall, so that
the endocardial/epicardial blood flow ratio remained
unchanged. Myocardial blood flow decreased parallel
to the decrease in blood pressure, from which it follows
that computed myocardial vascular resistance re-
mained unchanged.
Regional tissue and organ blood flows
and vascular resistances
Saline had no effect on any of the organ blood flows
(Table 3) or regional vascular resistances (Table 4),
which agrees with earlier findings from our laboratory
[16]. Z1046 produced a dose-dependent decrease in
liver blood flow (50 6 4%, p , 0.05, after the high dose),
which exceeded the decrease in blood pressure so that
vascular resistance increased. The low dose of Z1046
did not produce significant vasodilation of the regional
vascular beds. In contrast, the high dose of Z1046 pro-
duced vasodilator responses in the small intestine (34
Cardiovascular Effects of Z1046   539
PASTE TABLE 1 HERE
540   Duncker et al.
6 2% decrease in vascular resistance), spleen (43 6
7%), and kidneys (22 6 3%; all p , 0.05). The vasodila-
tion in the spleen was large enough to overcome the
decrease in blood pressure and to result in an increase
in blood flow (p , 0.05 vs. saline-induced change); blood
flow to the small intestine and kidneys was maintained.
Neither dose of Z1046 produced a significant change in
vascular resistance in the brain, adrenals, skin, or
skeletal muscle.
Discussion
Systemic hemodynamics
The open-chest pentobarbital anesthetized swine
preparation that was used in the present study con-
firmed previous observations of good hemodynamic
and myocardial functional stability [5,16], so that the
responses obtained in the two Z1046 treatment groups
(low-dose and high-dose) can be ascribed to the com-
pound. At the low dose (10 lg/kg) Z1046 produced a
15–20% decrease in cardiac output, which resulted in a
similar decrease in the mean aortic pressure, because
the trend toward a lower systemic vascular resistance
failed to reach levels of statistical significance. The
decrease in cardiac output was due to a decrease in
heart rate, because stroke volume did not change. An
unchanged stroke volume (and segment shortening) in
the face of a decrease in afterload could indicate a
negative inotropic effect of Z1046. This appears to be
supported by the decrease in LVdP/dtmax.
However, interpretation of changes in LVdP/dt max
as changes in contractility in the face of changes in
aortic blood pressure is complicated by the dependence
of LVdP/dtmax on diastolic aortic pressure (DAP). Thus,
no significant changes in LVdP/dtmax/DAP were ob-
served, suggesting that the Z1046-induced decrease in
LVdP/dtmax was primarily due to the decrease in DAP.
The bradycardia produced by Z1046 is in agreement
with inhibition of norepinephrine release from the
sympathetic nerve endings produced by presynaptic
D2-like receptor stimulation, while the absence of vaso-
dilation (particularly in the renal and mesenteric bed)
suggests negligible D1-like receptor stimulation with
this dose [1]. In contrast, Z1046 at a dose of 100 lg/kg
produced a similar decrease in mean aortic pressure,
but this was principally due to a decrease in systemic
vascular resistance as the trend toward a decrease in
cardiac output at 60 and 90 minutes after administra-
tion was not different from the time-related changes in
the saline-treated group.
Myocardial oxygen consumption decreased by 15%
with this dose. The minimal effect of the high dose of
Table 2. Myocardial blood flow and myocardial oxygen consumption responses to intravenous bolus injections of the dopamine
receptor agonist Z1046 in open-chest anesthetized swine
                                                                                               Minutes after administration                        
                                                            Group                               n      Baseline                    5                                  30                             90
Myocardial blood flow Saline 4 135 6 17 128 6 15 129 6 19 129 6 25
 (ml/min/100g) Z1046 10 lg/kg 6 152 6 8 120 6 16 109 6 12a,b 111 6 10a
Z1046 100 lg/kg 7 119 6 10 99 6 10a,b 97 6 9a 93 6 6a
Endo/epi Saline 4 1.05 6 0.22 1.05 6 0.22 1.08 6 0.22 1.05 6 0.22
Z1046 10 lg/kg 6 1.04 6 0.05 1.07 6 0.08 1.10 6 0.08 1.16 6 0.07
Z1046 100 lg/kg 7 1.20 6 0.08 1.16 6 0.15 1.31 6 0.12 1.24 6 0.07
Myocardial vascular Saline 4 0.64 6 0.09 0.64 6 0.07 0.67 6 0.13 0.69 6 0.13
 Resistance Z1046 10 lg/kg 6 0.55 6 0.04 0.66 6 0.06 0.68 6 0.05 0.66 6 0.02
  [mmHg/(ml/min/100 g)] Z1046 100 lg/kg 7 0.71 6 0.05 0.77 6 0.05 0.72 6 0.02 0.78 6 0.02
Arterial O2 sat (%) Saline 4 93.8 6 1.3 94.4 6  1.0 93.8 6 1.5 92.5 6 1.6
Z1046 10 lg/kg 6 92.8 6 0.9 94.7 6 0.9 93.6 6  0.6 93.4 6 0.7
Z1046 100 lg/kg 7 97.7 6 0.6 97.9 6 0.6 97.7 6  0.6 97.4 6 0.6
Coronary venous O2 sat (%) Saline 4 20.9 6 3.2 23.5 6 3.9 21.9 6 2.7 20.7 6 2.7
Z1046 10 lg/kg 6 26.3 6 1.3 24.0 6 1.6 22.9 6  2.3 21.4 6 2.6a,b
Z1046 100 lg/kg 7 30.6 6 1.9 23.6 6 1.2a,b 26.5 6 2.3a,b 26.1 6 1.9a,b
O2 extraction (%) Saline 4 77 6 4 75 6 4 76 6  3 77 6 3
Z1046 10 lg/kg 6 69 6 1 71 6 1 73 6 3 74 6  4
Z1046 100 lg/kg 7 69 6 2 73 6 2a,b 73 6  2a 73 6 2a
Myocardial O2 consumption Saline 4 537 6 71 492 6  51 498 6 70 500 6 104
 (Lmol/min/100 g) Z1046 10 lg/kg 6 496 6 37 408 6 61 374 6 37a 382 6 33a
Z1046 100 lg/kg 7 432 6 22 373 6 19a,b 371 6 35a 365 6 37a
Data are mean 6 SEM;
ap , 0.05 vs. corresponding baseline.
bp , 0.05 vs. saline-induced change from baseline.
endo/epi 5 subendocardial to subepicardial blood flow ratio; O2-sat 5 oxygen saturation.
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Z1046 on cardiac output was somewhat surprising. If
the low dose produced a decrease in cardiac output
via D2-like receptor–mediated inhibition of sympa-
thetic activity to the heart (which is suggested by the
decrease in heart rate and LVdP/dtmax), it would be
expected that a higher dose would produce an even
greater D2-like mediated decrease in heart rate and
cardiac output. It is possible that the high dose pro-
duced a direct stimulation of beta-adrenoceptors,
which antagonized the D2-like receptor–mediated ef-
fects on the heart. However, in view of observations
that Z1046 is devoid of significant beta-adrenoceptor
agonistic properties in guinea-pig atrium and trachea
[11], this would seem an unlikely explanation.
Alternatively, it is possible that the peripheral va-
sodilation produced by the high dose resulted in re-
flex-mediated activation of the sympathetic nervous
system and withdrawal of vagal activity, thereby par-
tially counteracting the direct effects of D2-like recep-
tor stimulation on sympathetic activity. This is sup-
ported by the observation that the higher dose
resulted in smaller decreases in heart rate compared
with the low dose and that a small increase in stroke
volume occurred 5 minutes after its administration.
Nonetheless, even with this dose we failed to observe
reflex-mediated increases in heart rate and
LVdP/dtmax, which contrasts with previous observa-
tions with other vasodilators, such as the dihy-
dropyridine calcium antagonist nisoldipine and the
K1ATP channel opener bimakalim, in the same experi-
mental model [15,16].
Regional vascular resistances
The systemic vasodilation produced by 1046 was lo-
cated primarily in the kidneys, small intestine, and
spleen. Vasodilation in the kidneys and small intestine
was likely to be the result of stimulation of D1-like
receptors, which are abundant in these vascular beds.
In support of this hypothesis, we have previously ob-
served in the same swine model that dopamine (in the
absence or presence of nonselective alpha- and beta-
adrenergic receptor blockade; Figure 2) or the selec-
tive D1-like receptor agonist fenoldopam produced va-
sodilation in these beds [5]. On the other hand, the
absence of significant cerebral vasodilation, which we
did observe previously when we infused fenoldopam or
dopamine in the presence of adrenergic receptor block-
ade, suggests that the vasodilation produced by the
Table 3. Regional blood flow responses to intravenous bolus injections of the dopamine receptor agonist Z1046 in open-chest
anesthetized swine.
                                                                                            Minutes after administration                           
                                        Group                                 n                Baseline                        5                                   30                                 90
Brain Saline 4 28 6 3 26 6 2 27 6 3 27 6 2
Z1046,10 lg/kg 6 32 6 2 31 6 3 31 6 3 31 6  2
Z1046,100 lg/kg 7 36 6 4 32 6 3 31 6 2 31 6  2
Kidneys Saline 4 241 6 36 232 6 37 239 6 44 255 6 47
Z1046,10 lg/kg 6 258 6 23 271 6 22 253 6 22 257 6 22
Z1046,100 lg/kg 7 268 6 19 303 6 18 280 6 17 288 6 17
Small intestine Saline 4 39 6 8 43 6 10 40 6 8 43 6 5
Z1046,10 lg/kg 6 41 6 4 41 6 4 40 6 4 38 6  3
Z1046,100 lg/kg 7 40 6 4 53 6 4c 39 6  3 41 6 4
Adrenals Saline 4 102 6 19 101 6 22 109 6 21 135 6 26
Z1046,10 lg/kg 6 98 6 15 94 6 14 93 6 15 106 6 8
Z1046,100 lg/kg 7 143 6 36 127 6 16 116 6 13 116 6 11
Liver Saline 4 46 6 8 40 6 7 49 6 1 55 6 8
Z1046,10 lg/kg 6 54 6 13 41 6 9 39 6 9 45 6  12
Z1046,100 lg/kg 7 70 6 8 35 6 5a,b 58 6  8a 50 6 6a
Spleen Saline 4 153 6 11 148 6 9 145 6 12 155 6  8
Z1046,10 lg/kg 6 170 6 25 168 6 30 153 6 25 164 6 26
Z1046,100 lg/kg 7 131 6 20 206 6 21c,b 141 6 15 120 6 15
Skeletal muscle Saline 4 4.9 6 0.7 4.7 6 0.7 4.4 6  0.7 4.3 6 0.8
Z1046,10 lg/kg 6 8.3 6 1.7 5.6 6 0.8 5.0 6  0.6 4.8 6 0.5
Z1046,100 lg/kg 7 7.0 6 1.3 5.8 6 1.1 5.1 6  0.5 4.0 6 0.2
Skin Saline 4 1.70 6 0.33 1.23 6 0.23 1.19 6 0.10 1.09 6 0.07
Z1046,10 lg/kg 6 2.09 6 0.46 2.81 6 1.06 2.09 6  0.55 1.91 6 0.21
Z1046,100 lg/kg 7 2.86 6 1.20 1.64 6 0.18 1.84 6 0.61 1.65 6 0.28
Date are presented as mean 6 SEM.
ap , 0.05 vs. corresponding baseline.
bp , 0.05 vs. saline-induced change from baseline.
Blood flows are presented in ml/min/100 g.
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high dose of Z1046 occurred, at least in part, via an-
other mechanism. Recent investigations revealed that
there is more than one D1-like receptor subtype (D1a
and D1b receptors) [17]. It is possible that Z1046 has
little affinity for the cerebral D1-like receptor subtype
but does stimulate the mesenteric and renal D1-like
receptor subtype. Involvement of D1-like receptors in
the renal vasodilation produced by Z1046 is supported
by data obtained in anesthetized dogs [10]. Thus pre-
treatment with the selective D1-like receptor antago-
nist SCH23390 abolished the renal vasodilation pro-
duced by Z1046 administered at a dose of 30 lg/kg,
intravenously [10]. The vasodilation in the porcine
spleen may be due to stimulation of presynaptic D2-like
receptors. Thus, we previously observed that nonselec-
tive alpha- and beta-adrenergic receptor blockade
abolished the vasodilator response to dopamine in the
spleen, whereas the vasodilation in the kidneys and
small intestine persisted, suggesting that the vasodila-
tor response to Z1046 in the spleen could be due to
D2-like mediated withdrawal of alpha-adrenergic tone.
It is possible that the splenic D2-like vasodilation is
species specific for swine because vasodilation pro-
duced by Z1046 in the isolated rabbit splenic artery is
antagonized by the D1-like receptor antagonist
SCH23390.
In anesthetized dogs, Z1046 (30 lg/kg, intravenous)
was reported to produce a 47% decrease (which was
D2-receptor mediated) in the resistance of the femoral
bed, which represents mainly skeletal muscle [10]. In
contrast, we failed to observe vasodilation in skeletal
muscle tissue in the present study. Similarly, we pre-
viously reported that dopamine, either in the absence
or presence of alpha- and beta-adrenergic receptor
blockade, failed to elicit a vasodilation response in por-
cine skeletal muscle [6]. It is possible that in pentobar-
bital anesthetized dogs sympathetic activity is higher
than in swine, due to the pentobarbital-induced vagal
withdrawal that occurs in dogs [18]. This would allow
D2-like receptor stimulation to produce vasodilation
via inhibition of alpha-adrenergic constriction in dogs.
In the present study, Z1046 had no effect on coro-
nary vascular resistance, because decrease in myocar-
dial blood flow (which was the result of decreased myo-
cardial oxygen requirements) paralleled the decrease
in aortic blood pressure. It has been suggested that
D1-like receptor stimulation produces coronary vasodi-
lation in anesthetized dogs [2,19,20], although one re-
Table 4. Regional vascular resistance responses to intravenous bolus injections of the dopamine receptor agonist Z1046 in open-chest
anesthetized swine
                                                                                              Minutes after administration                         
                                        Group                                   n                 Baseline                       5                                  30                                   90
Brain Saline 4 3.02 6 0.28 3.04 6 0.16 2.99 6 0.30 2.98 6 0.16
Z1046,10 lg/kg 6 2.70 6 0.29 2.51 6 0.31 2.38 6  0.21 2.36 6 0.22
Z1046,100 lg/kg 7 2.62 6 0.34 2.55 6 0.25 2.35 6 0.21 2.31 6 0.16
Kidneys Saline 4 0.36 6 0.05 0.37 6 0.05 0.37 6  0.07 0.35 6 0.06
Z1046,10 lg/kg 6 0.35 6 0.05 0.30 6 0.05 0.30 6  0.04 0.30 6 0.05
Z1046,100 lg/kg 7 0.34 6 0.03 0.26 6 0.02a,b 0.26 6 0.02a,b 0.25 6 0.02a,b
Small intestine Saline 4 2.26 6 0.34 2.04 6 0.30 2.22 6 0.40 1.93 6 0.25
Z1046,10 lg/kg 6 2.15 6 0.29 1.92 6 0.26 1.87 6  0.20 1.95 6 0.17
Z1046,100 lg/kg 7 2.29 6 0.24 1.49 6 0.12a,b 1.90 6 0.17a 1.79 6 0.17a
Adrenals Saline 4 0.89 6 0.16 0.86 6 0.13 0.81 6  0.15 0.64 6 0.08
Z1046,10 lg/kg 6 0.92 6 0.12 0.86 6 0.11 0.85 6  0.11 0.70 6 0.06
Z1046,100 lg/kg 7 0.82 6 0.16 0.67 6 0.08 0.66 6 0.08 0.64 6 0.06
Liver Saline 4 2.03 6 0.54 2.24 6 0.52 1.60 6 0.05 1.51 6 0.14
Z1046,10 lg/kg 6 2.53 6 0.83 4.31 6 2.55 3.00 6  1.08 2.39 6 0.68
Z1046,100 lg/kg 7 1.35 6 0.17 2.49 6 0.40a,b 1.41 6 0.68 1.56 6 0.24
Spleen Saline 4 0.54 6 0.04 0.54 6 0.05 0.55 6 0.04 0.52 6 0.05
Z1046,10 lg/kg 6 0.54 6 0.08 0.47 6 0.04 0.50 6  0.05 0.48 6 0.05
Z1046,100 lg/kg 7 0.75 6 0.1 0.40 6 0.05a,b 0.54 6 0.06 0.64 6 0.08
Skeletal muscle Saline 4 17.4 6 2.2 17.8 6 2.5 19.0 6 2.3 20.3 6 3.1
Z1046,10 lg/kg 6 13.2 6 2.9 14.3 6 1.9 15.7 6  2.5 16.0 6 2.2
Z1046,100 lg/kg 7 14.5 6 2.1 15.5 6 2.4 14.6 6  1.2 18 6 0.7
Skin Saline 4 53 6 9 69 6 9 67 6 6 74 6 2
Z1046,10 lg/kg 6 47 6 18 43 6 18 41 6 15 34 6 7
Z1046,100 lg/kg 7 52 6 10 50 6 6 35 6 6 49 6 7
Data presented as mean 6 SEM.
ap , 0.05 vs. corresponding baseline.
bp , 0.05 vs. saline-induced change from baseline.
Vascular resistances are presented in mmHg/(ml/min/100 g).
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port in dogs was negative [21]. In swine, we also failed
to observe D1-like mediated coronary vasodilation af-
ter intracoronary infusions of fenoldopam or intrave-
nous infusions of dopamine in the presence of adrener-
gic blockade [5]. These findings suggest that the
presence of D1-like receptors in the coronary circula-
tion is species dependent. In human isolated coronary
arteries precontracted with norepinephrine, fenol-
dopam failed to elicit a vasodilator response in 6 out of
7 patients [22], implying that human conduit coronary
arteries may also be devoid of D1-like receptors.
Conclusions
In open-chest swine, the novel mixed dopamine recep-
tor agonist Z1046 is a hypotensive agent that produces
minimal reflex activation. Future research is war-
Fig. 2. Hexagonals showing the percent change in systemic and regional vascular resistance
in response to the mixed D1-like/D2-like receptor agonist Z1046 in the present study (upper
panels), and to dopamine in the absence (middle panels) and presence of alpha- and beta-
adrenergic receptor blockade (lower panels) [5]. Note that while Z1046 dilates the splenic,
renal, and mesenteric bed, it lacks significant cerebral vasodilation at the doses studied.
Dopamine dilated the splenic, renal, mesenteric, and cerebral vascular beds, and splenic
artery dilation was abolished by pretreatment with adrenergic receptor blockade.
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ranted to determine the efficacy of this class of drugs
in animal models of cardiovascular disease, such as hy-
pertension and heart failure.
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